April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- Proposed Oregon legislation blocks AI tools from using 'nurse' title
- Communications skills keep surgical patients engaged, informed
- Study: Daytime meals protect heart health in night shift workers
- Borescope inspections reveal widespread contamination in lumened surgical instruments
- Nursing workforce faces high turnover despite signs of recovery
- FDA issues early alerts for intravascular catheters
- Market volatility threatens hospitals’ liquidity as tariff-driven costs rise
- Study: CT scan radiation could drive 5% of future cancer cases
- New studies, surgical feats advance organ transplant medicine
- Commentary: Cyberattacks threaten financial survival of surgical practices
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement